Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

2.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

3.

Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.

Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, Beuzen JN, Carson W, Corey-Lisle PK, Falissard B, Jody DN, Kujawa MJ, L'italien G, Marcus RN, McQuade RD, Ray S, Van Peborgh P; IAQ Validation Study Group.

Psychiatry Res. 2005 Sep 15;136(2-3):211-21.

PMID:
16115690
4.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

5.

Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.

Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keitner GI, Kornstein SG, Arnow B, Klein DN, Manber R, Dunner DL, Gelenberg AJ, Kocsis JH, Nemeroff CB, Fawcett J, Thase ME, Russell JM, Jody DN, Borian FE, Keller MB.

Neuropsychopharmacology. 2005 Feb;30(2):405-16.

6.

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.

Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG; Aripiprazole Study Group.

Psychopharmacology (Berl). 2003 Apr;166(4):391-9. Epub 2003 Feb 28.

PMID:
12610718
7.

Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.

Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D.

J Clin Psychiatry. 2001 Jan;62(1):24-9.

PMID:
11235924
8.

Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia.

Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L, Lieberman JA.

Schizophr Res. 1995 Sep;17(1):47-58.

PMID:
8541249
9.

Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.

Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, et al.

Am J Psychiatry. 1995 May;152(5):698-703.

PMID:
7726309
10.

Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls.

Levy DL, Smith M, Robinson D, Jody D, Lerner G, Alvir J, Geisler SH, Szymanski SR, Gonzalez A, Mayerhoff DI, et al.

Biol Psychiatry. 1993 Oct 15;34(8):507-14.

PMID:
8274577
11.

Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates.

Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy DL, Bogerts B, Degreef G, Mayerhoff DI, Cooper T.

Arch Gen Psychiatry. 1993 May;50(5):357-68.

PMID:
8489325
12.

Time course and biologic correlates of treatment response in first-episode schizophrenia.

Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M.

Arch Gen Psychiatry. 1993 May;50(5):369-76.

PMID:
8098203
13.

Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia.

Levy DL, Bogerts B, Degreef G, Dorogusker B, Waternaux C, Ashtari M, Jody D, Geisler S, Lieberman JA.

Schizophr Res. 1992 Oct;8(1):1-10.

PMID:
1419933
14.

Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients.

Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir JM, Lieberman JA.

Arch Gen Psychiatry. 1992 Jul;49(7):531-7.

PMID:
1627044
15.

Anticholinergic delirium caused by retreatment with clozapine.

Szymanski S, Jody D, Leipzig R, Masiar S, Lieberman J.

Am J Psychiatry. 1991 Dec;148(12):1752. No abstract available.

PMID:
1957942
16.

Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.

Jody D, Lieberman JA, Geisler S, Szymanski S, Alvir JM.

Psychopharmacol Bull. 1990;26(2):224-30.

PMID:
2236460
17.

Treatment outcome of first episode schizophrenia.

Lieberman J, Jody D, Geisler S, Vital-Herne J, Alvir JM, Walsleben J, Woerner MG.

Psychopharmacol Bull. 1989;25(1):92-6. No abstract available.

PMID:
2772122

Supplemental Content

Support Center